Often, there is a delay in the diagnosis of inflammatory back pain (IBP) in the primary care setting. This may be attributed to the inability of healthcare providers to distinguish between inflammatory and mechanical back pain. This study aimed to evaluate primary care physicians' current practices for assessing patients with IBP using clinical, radiographic, and laboratory tests. A questionnaire-based survey was emailed to all primary care physicians in the western region of Saudi Arabia by the Saudi Commission of Health Specialists from February to May 2021. The questionnaire included data about axial spondyloarthropathy based on the Calin, Berlin, and European Spondyloarthropathy Study Group criteria. A total of 103 primary care physicians responded who represented around 24% of primary care physicians at primary healthcare. The most often perceived IBP symptoms include a response to NSAIDs, morning stiffness lasting >30 minutes, age of onset <45 years old, duration of back pain >3 months, and improvement with exercise. The most frequently questioned patient or family history conditions were peripheral arthritis (92.2%), family history of spondyloarthritis (83.5%), and inflammatory bowel disease (97.6%). The most-reported investigations were CRP/ESR (86.4%) and spinal radiography (66%). For treatment of IBP, NSAIDs were most prescribed (48.6%), followed by physiotherapy (45.6%) and disease-modifying anti-rheumatic drugs (41.7%). Primary care physicians were more confident in management of mechanical back pain than IBP (P < .001). Primary care physicians have good knowledge of IBP symptoms but not of disease-specific features and modest confidence in evaluating patients with IBP, indicating the need for educational programs and a more effective, feasible referral strategy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622622 | PMC |
http://dx.doi.org/10.1097/MD.0000000000031626 | DOI Listing |
Ann Oncol
February 2025
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address:
Background: We predicted the number of cancer deaths and rates for 2025 in the European Union (EU), its five most populous countries, and the UK, focusing on breast cancer.
Materials And Methods: We derived population data and death certificates for all cancers and major sites for the EU, France, Germany, Italy, Poland, Spain, and the UK since 1970, from the World Health Organization and United Nations databases. Estimates for 2025 were computed by linear regression on recent trends identified through Poisson joinpoint regression, considering the slope of the most recent trend segment.
Am J Geriatr Psychiatry
February 2025
Department of Psychiatry (AJCS, EJG), Leiden University Medical Center, Leiden, The Netherlands; Health Campus The Hague (EJG), Department of Public Health & Primary Care, Leiden University Medical Center, Leiden, The Netherlands. Electronic address:
Background: The prevalence of depressive symptoms, apathy, and cognitive decline increases with age. Understanding the temporal dynamics of these symptoms could provide valuable insights into the early stages of cognitive decline, allowing for more timely and effective treatment and management.
Methods: Participants from the Prevention of Dementia by Intensive Vascular Care (preDIVA) trial cohort with baseline and ≥3 follow-up measurements were included, with a median of 7.
Res Social Adm Pharm
March 2025
Department of Primary Care and Medical Education, Institute of Medicine, University of Tsukuba, 1-1-1, Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. Electronic address:
Background: Deprescribing by physicians based on the suggestions of community pharmacists is useful to ensure medication safety. Pharmacist-led deprescribing is not always implemented smoothly because of communication gaps between physicians and pharmacists. Our previous study found that assertiveness, as a communication style, is associated with pharmacist-initiated prescription changes for medication safety; however, its association with community pharmacist-led deprescribing is unclear.
View Article and Find Full Text PDFRes Social Adm Pharm
March 2025
WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute), Stubenring 6, 1010, Vienna, Austria; Department of Health Policy, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK. Electronic address:
Background: Community pharmacy appears to have undergone considerable change over the years.
Objectives: The objective of this research is to study the range of community pharmacy services provided in late stages of the COVID-19 pandemic and during the last decades and to identify potential drivers for change.
Methods: Four European countries (Austria, England, Estonia, and Portugal), which represent a balance in terms of income, organization of the health system and pharmacy services, were selected as case studies.
Pain Manag Nurs
March 2025
University Center for Health Sciences, University of Guadalajara, Jalisco, México. Electronic address:
Purpose/objectives: Analyze the meaning of pain and suffering experienced by patients with end-stage cancer from a systemic perspective.
Design: Qualitative study based on General Systems Theory.
Sample/participants: Ten patients with terminal stage cancer were interviewed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!